BetterLife Pharma Income Statement

Financials in millions CAD. Fiscal year is February - January.

Millions CAD. Fiscal year is Feb - Jan.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jan '26 Jan 31, 2026	Jan '25 Jan 31, 2025	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022
Selling, General & Admin	1.72	4.3	2.64	6.56	4.53
Research & Development	0.09	0.42	0.57	2.68	5.42
Operating Expenses	1.81	4.72	3.21	9.26	9.97
Operating Income	-1.81	-4.72	-3.21	-9.26	-9.97
Interest Expense	-0.23	-0.32	-0.05	-0.07	-0.06
Currency Exchange Gain (Loss)	0.2	-0.28	-0.03	-0.2	-0.24
Other Non Operating Income (Expenses)	0.17	0.73	-0.17	-0	-1.07
EBT Excluding Unusual Items	-1.67	-4.59	-3.46	-9.53	-11.33
Gain (Loss) on Sale of Assets	-	-	-	-	0.19
Legal Settlements	-	0.56	0.13	0.26	-0.56
Other Unusual Items	0.16	0.42	0.44	-0.1	-0.29
Pretax Income	-1.51	-3.62	-2.9	-9.37	-11.99
Income Tax Expense	-	-	-	-	0.17
Earnings From Continuing Operations	-1.51	-3.62	-2.9	-9.37	-12.16
Minority Interest in Earnings	0.02	0.1	0.01	0.36	-
Net Income	-1.5	-3.52	-2.89	-9.02	-12.16
Net Income to Common	-1.5	-3.52	-2.89	-9.02	-12.16
Shares Outstanding (Basic)	146	124	109	87	75
Shares Outstanding (Diluted)	146	124	109	87	75
Shares Change (YoY)	17.77%	13.34%	26.25%	14.70%	179.24%
EPS (Basic)	-0.01	-0.03	-0.03	-0.10	-0.16
EPS (Diluted)	-0.01	-0.03	-0.03	-0.10	-0.16
Free Cash Flow	-0.63	-2.02	-2.47	-1.5	-11.2
Free Cash Flow Per Share	-0.00	-0.02	-0.02	-0.02	-0.15
EBITDA	-	-	-3.19	-9.24	-9.95
D&A For EBITDA	-	-	0.02	0.02	0.02
EBIT	-1.81	-4.72	-3.21	-9.26	-9.97
Advertising Expenses	-	-	-	0.12	0.44